Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;141(2):344-52.
doi: 10.1017/S0950268812000763. Epub 2012 May 8.

Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England

K E Chapman  1 , D Wilson  2 , R Gorton  1
Affiliations

Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England

K E Chapman et al. Epidemiol Infect. 2013 Feb.

Abstract

The 7-valent pneumococcal conjugate vaccine (PCV7) has been included in the routine childhood immunization programme in the UK since September 2006. A population-based study of serotypes causing invasive pneumococcal disease (IPD) post-PCV7 in North East England was conducted using data from a regional enhanced IPD surveillance system. Overall, there was a 20% reduction [95% confidence interval (CI) 5-32] from 12·1 cases/100 000 population in 2006/2007 to 9·7 in 2009/2010. There was a fall in IPD caused by PCV7 serotypes in all age groups, with reductions of 90% (95% CI 61-99) in children aged <5 years, 50% (95% CI 4-75) in persons aged 5-64 years and 66% (95% CI 40-82) in adults aged ⩾65 years. There was a non-significant increase in IPD caused by non-PCV7 serotypes in children aged <5 years of 88% (95% CI -10 to 312) and adults aged ⩾65 years of 12% (95% CI -19 to 50), which was largely caused by serotypes 7F, 19A and 22F. Replacement disease appears to have reduced the benefits of PCV7 in North East England.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Changes in incidence (cases/100 000 population) of invasive pneumococcal disease caused by (a) PCV7 and (b) non-PCV7 serotypes by age group in North East England, 2006–2010.
Fig. 2.
Fig. 2.
Changes in incidence (cases/100 000 population) of individual PCV7 serotypes causing invasive pneumococcal disease in North East England, 2006–2010.
Fig. 3.
Fig. 3.
Proportion of invasive pneumococcal disease cases caused by PCV7 and PCV13 serotypes by age group in North East England, 2009/2010.
Fig. 4.
Fig. 4.
Changes in the number of invasive pneumococcal disease cases caused by serotypes 1, 7F, 19A and 22F by age group in North East England, 2006–2010 (note scales differ).
See this image and copyright information in PMC

References

    1. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infectious Diseases 2005; 5: 83–93. - PubMed
    1. Brueggemann AB, et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. Journal of Infectious Diseases 2003; 187: 1424–1432. - PubMed
    1. Sandgren A, et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. Journal of Infectious Diseases 2004; 189: 785–796. - PubMed
    1. Pilishvili T, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010; 201: 32–41. - PubMed
    1. Centres for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. Morbidity and Mortality Weekly Report 2005; 54: 893–897. - PubMed

Publication types

MeSH terms